California Institute for Regenerative Medicine, Oakland, California, USA.
Accendo Scientific, San Francisco, California, USA.
Stem Cells Transl Med. 2017 Oct;6(10):1823-1828. doi: 10.1002/sctm.17-0047. Epub 2017 Aug 9.
The mission of the California Institute of Regenerative Medicine (CIRM) is to accelerate treatments to patients with unmet medical needs. In September 2016, CIRM sponsored a workshop held at the University of California, Los Angeles, to discuss regenerative medicine approaches for treatment of lung diseases and to identify the challenges remaining for advancing such treatments to the clinic and market approval. Workshop participants discussed current preclinical and clinical approaches to regenerative medicine in the lung, as well as the biology of lung stem cells and the role of stem cells in the etiology of various lung diseases. The outcome of this effort was the recognition that whereas transient cell delivery approaches are leading the way in the clinic, recent advances in the understanding of lung stem cell biology, in vitro and in vivo disease modeling, gene editing and replacement methods, and cell engraftment approaches raise the prospect of developing cures for some lung diseases in the foreseeable future. In addition, advances in in vitro modeling using lung organoids and "lung on a chip" technology are setting the stage for high quality small molecule drug screening to develop treatments for lung diseases with complex biology. Stem Cells Translational Medicine 2017;6:1823-1828.
加利福尼亚再生医学研究所（CIRM）的使命是加速为有未满足医疗需求的患者提供治疗方法。2016 年 9 月，CIRM 赞助了在加利福尼亚大学洛杉矶分校举行的一次研讨会，讨论了用于治疗肺部疾病的再生医学方法，并确定了将这些治疗方法推进临床和市场批准所面临的挑战。研讨会参与者讨论了肺部再生医学的当前临床前和临床方法，以及肺部干细胞生物学和干细胞在各种肺部疾病发病机制中的作用。这一努力的结果是认识到，尽管短暂的细胞输送方法在临床上处于领先地位，但对肺部干细胞生物学的理解、体外和体内疾病建模、基因编辑和替代方法以及细胞移植方法的最新进展，提高了在可预见的未来为一些肺部疾病开发治愈方法的前景。此外，使用肺类器官和“芯片上的肺”技术进行体外建模的进展为开发治疗具有复杂生物学的肺部疾病的小分子药物筛选奠定了基础。《干细胞转化医学》2017；6：1823-1828。
